Genetics of 22q11.2 Deletion Syndrome {#s1}
=====================================

Chromosome 22q11.2 deletion syndrome (22q11.2del) (OMIM \#'s 188400, 192430, 611867) is the most common chromosomal microdeletion reported in humans, affecting \~1/4,000 individuals ([@B16]; [@B66]; [@B43]; [@B94]). Screening fetuses for 22q11.2del by prenatal procedures reveals an even higher frequency of \~1/1,000, suggesting a high morbidity *in utero* ([@B156]; [@B47]). The disease is multi-syndromic of contrasting severity and penetrance among those affected. It can include congenital heart disease (CHD; especially conotruncal malformations, tetralogy of Fallot, aortic arch abnormalities, truncus arteriosus, ventricular septal defects and vascular rings) and abnormalities of the palate (clefts and velopharyngeal incompetence) ([@B66]; [@B43]; [@B50]; [@B94]; [@B96]; [@B107]; [@B145]). Hypoplasia of the thymus, hypoparathyroidism, dysmorphic facial features, renal and/or skeletal anomalies are also common ([@B66]; [@B94]; [@B145]). Those in whom an immune deficiency is identified are often classed as having DiGeorge syndrome ([@B28]; [@B66]; [@B90]; [@B89]). DiGeorge syndrome is first suggested following newborn screens for detecting the levels T-cell receptor excision circles (TRECs) as a measure of T cell output from the thymus ([**Table 1**](#T1){ref-type="table"}) ([@B16]; [@B66]; [@B94]). Low TRECs can be an indicator of DiGeorge syndrome, with the diagnosis of 22q11.2del subsequently established by FISH or chromosomal microarray technologies ([@B70]; [@B151]; [@B130]; [@B119]). The heterogeneous congenital problems for 22q11.2del patients arise from defective remodeling of the pharyngeal region during embryogenesis ([@B144]; [@B7]; [@B66]; [@B43]; [@B50]; [@B94]; [@B4]). Impacted is the second heart field and the pharyngeal arch arteries, which form the outgrowth vessels of the heart, as well as the pharyngeal pouches (PP), with the 3^rd^ PP forming the thymic lobes and inferior parathyroids ([@B82]; [@B58]; [@B83]; [@B100]; [@B158]; [@B22]; [@B1]). Over time, individuals with 22q11.2del often exhibit developmental delay and autoimmune manifestations, with their malignancy risk higher compared to the general population. Autism and autism spectrum, anxiety, attention deficit disorders and psychiatric illnesses like schizophrenia are common ([@B91]; [@B66]; [@B61]; [@B107]; [@B145]; [@B172]). Males and females with 22q11.2del are equally affected, regardless of their racial/ethnic grouping ([@B112]; [@B66]; [@B94]; [@B68]). The least concordant phenotypes occur in children of African descent ([@B68]). Not surprisingly given the numerous organ systems affected, 22q11.2del patients have a diminished life expectancy ([@B121]). Mid-aged 22q11.2del individuals have a median life expectancy of 42 years compared to normal sibling controls (60--70 yrs. of age) ([@B92]; [@B8]; [@B9]; [@B121]). With such a wide gamut of problems, a multi-disciplinary clinical approach is often needed to provide adequate care for children and adolescents with 22q11.2del. This can definitely improve the overall quality of life for 22q11.2del patients, which is lower than normal ([@B43]; [@B94]). Yet, health care costs for 22q11.2del patients can reach a staggering \$1,000,000 during their first 20 years of life ([@B17]).

###### 

Clinical manifestations of 22q11.2 and 22q11.2-like deletion syndromes.

                                                                             Chromosomal regions affected                                                                                   
  -------------------------------------------------------------------------- ------------------------------ --------------------------------------- --------------------------------------- ---------------------------------------
                                                                             22q11.2                        10p14-13                                4q34.1-q35.2                            3p10.3
  Frequency                                                                  1/4000                         \>100 individuals                       rare                                    rare
  Length of DNA deletion                                                     3 Mb or 1.5 Mb                 5 Mb                                    17.4 Mb                                 300 kb
  **Clinical Phenotype**                                                     \% occurrence                                                                                                  
  Congenital heart disease (CHD)[^a^](#fnT1_1){ref-type="table-fn"}          75%                            82%                                     15%                                     yes
  Immune deficiency (thymic hypoplasia)[^b^](#fnT1_2){ref-type="table-fn"}   50--70%                        17%                                     nr[^d^](#fnT1_4){ref-type="table-fn"}   yes
  Hypocalcemia (hypoparathyroidism)                                          35%                            22%                                     nr[^d^](#fnT1_4){ref-type="table-fn"}   yes
  Dysmorphic craniofacial features                                           50%                            50%                                     95-99%                                  yes
  Developmental delay                                                        50%                            80-90%                                  10%                                     yes
  Renal anomalies                                                            14%                            5%                                      nr[^d^](#fnT1_4){ref-type="table-fn"}   yes
  Skeletal defects                                                           60%                            nr[^d^](#fnT1_4){ref-type="table-fn"}   55%                                     nr[^d^](#fnT1_4){ref-type="table-fn"}
  Learning problems                                                          70%                            80-99%                                  65%                                     yes
  Psychiatric disorders[^c^](#fnT1_3){ref-type="table-fn"}                   30%                            nr[^d^](#fnT1_4){ref-type="table-fn"}   nr[^d^](#fnT1_4){ref-type="table-fn"}   nr[^d^](#fnT1_4){ref-type="table-fn"}
  Gastrointestinal abnormalities                                             30%                            nr[^d^](#fnT1_4){ref-type="table-fn"}   nr[^d^](#fnT1_4){ref-type="table-fn"}   nr[^d^](#fnT1_4){ref-type="table-fn"}
  Digital malformations (polydactyly)                                        30%                            30-80%                                  88%                                     nr[^d^](#fnT1_4){ref-type="table-fn"}

CHD includes interrupted aortic arches, Tetralogy of Fallot, right subclavian artery defects, ventricular septal defects, pulmonary atresia, and other outflow tract anomalies.

Immune deficiency is defined with peripheral T cell counts less than 1500 cells/µl.

Psychiatric disorders can include autism, schizophrenia, seizure disorder.

nr, not reported.

Ninety percent of individuals with 22q11.2del have a 3 Mb microdeletion on chromosome 22, resulting in a hemizygosity of approximately 106 genes ([**Figure 1**](#f1){ref-type="fig"}) ([@B50]; [@B94]). Forty-six of these are protein coding, 24 are pseudogenes and the remainder comprise non-coding RNAs; 7 microRNAs (miRNAs), 12 long noncoding RNAs (lncRNAs), 2 small nucleolar RNAs (snoRNAs), and additional undefined transcripts. About 5-8% of 22q11.2del individuals have a smaller, nested deletion of 1.5 Mb ([**Figure 1**](#f1){ref-type="fig"}). This leads to a haploinsufficiency of 30 coding genes, as well as 6 and 9 of the miRNAs and lncRNAs affected with the longer deletion, respectively. Both types of deletions are due to erroneous chromosomal rearrangements during meiosis. These exchanges involve 8 large, paralogous low copy repeats (LCRs), or segmental duplications (A--H) that are distributed along a 5.6 Mb segment of chromosome 22q11.2 ([**Figure 1**](#f1){ref-type="fig"}) ([@B134]; [@B55]). DNA recombination of the LCRs, which are 96% sequence identical, during cross-over exchanges results in erroneous deletions or duplications ([@B133]; [@B134]; [@B15]). Distributed within or around the LCRs are 8 long intergenic noncoding RNAs (lncRNAs). These lncRNAs contain Translocation Breakpoint Type A (TBTA) sequences with homology to FAM230C, a lncRNA on chromosome 13 ([@B32]). Such lncRNAs may contribute to the deletions *via* the translocation breakpoint sequences. The most frequent deletion in 22q11.2del patients spans LCR A-D (3 Mb), with a less frequent deletion between LCR A-B (1.5 Mb) ([**Figure 1**](#f1){ref-type="fig"}). These are referred to as proximal deletions and are causal to the majority of clinical phenotypes ascribed to 22q11.2del. The actual breakpoint location within the LCR does not have a major role in 22q11.2del phenotypes ([@B14]). A rare number of individuals have deletions between LCR B-D or LCR C-D, which are referred to as central deletions. These deletions can also cause CHD and/or neurological abnormalities ([@B128]; [@B19]). Even more infrequent are deletions between LCR C-E, LCR D-E, and LCR E-F, although the reported clinical phenotypes are not characteristic of 22q11.2del ([@B128]; [@B135]; [@B19]; [@B50]).

![Genetic organization of the human chromosome 22q11.2 locus and synteny on murine chromosome 16. Human chromosome 22 is approximately 51 million base pairs. The region affected by the 22q11.2 chromosomal deletions and duplications spans approximately 4 Mb, with 8 low copy repeats (LCR A-LCR H) causal to this distributed throughout this region. LCR A-LCR D are shown. Recombination of these highly homologous sequences (also called segmental duplications) results in proximal, central, and distal (not shown) deletions affecting both coding and noncoding DNA segments. The proximal deletions are responsible for the classic clinical features of 22q11.2del, which includes DiGeorge syndrome. The location of the coding genes, and noncoding RNAs including miRNAs and lncRNAs, are shown for the proximal region of chromosome 22q11.2. The corresponding genes on the murine locus are connected with lines, which reveals a flipping of the locus and a break containing distinct genes. Three of the more commonly used mouse models of 22q11.2del that replicate many clinical features of 22q11.2del are shown, named as the Df16(A), Df1 and Lgdel lines.](fgene-10-01365-g001){#f1}

The role of many of the genes whose haploinsufficiency contributes to the congenital malformations, immune system complications, neurological issues and other clinical phenotypes are well-described and discussed in many reviews ([@B167]; [@B9]; [@B94]; [@B96]; [@B107]; [@B106]; [@B145]; [@B172]). Among some of the more well-characterized genes are *T-Box 1 Transcription Factor* (*TBX1*)*, DiGeorge Syndrome Critical Region 8* (*DGCR8*), *Crk-like Adaptor Protein L* (*CRKL*), *Proline Dehydrogenase* (*PRODH*), *Reticulon 4 Receptor* (*RTN4R*), *Zinc-finger DHHC-type Containing 8* (*ZDHHC8*), *Catechol-O-Methyl Transferase* (*COMT*), *Guanine Nucleotide Binding Protein b-polypeptide 1-Like* (*GNB1L*), *Septin 5* (*SEP5*) and *Glycoprotein Ib Platelet Subunit Beta* (*GP1BB*). Yet, the haploinsufficiency of these genes is clearly unable to explain the heterogeneous penetrance and severity of clinical phenotypes that differ from patient to patient. This is even noted among family members with the same mutation in *TBX1* and with genetically identical in-bred strains of mice used as models of 22q11.2del syndrome. In this review, we present recent findings revealing how variations in the expression of *TBX1*, the functions of *DGCR8*, and the miRNAs and long noncoding RNAs within and outside the 22q11.2 locus can influence the severity of the clinical manifestations of 22q11.2del ([**Tables 1**](#T1){ref-type="table"}--[**3**](#T3){ref-type="table"}). We also review data identifying gene duplications, CNVs, SNPs, and other chromosomal abnormalities that impact 22q11.2del patients and/or result in overlapping 22q11.2-like phenotypes in some individuals.

###### 

Epigenetic modifiers of 22q11.2 locus: Noncoding RNA regulators and noncoding RNAs.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Type of RNA                                      RNA transcript affected                           Location on 22q11.2                                              Murine Homologs                       Confirmed targets[^b^](#fnT2_2){ref-type="table-fn"}   Tissue Expression                                               Pathways affected[^c^](#fnT2_3){ref-type="table-fn"}
  ------------------------------------------------ ------------------------------------------------- ---------------------------------------------------------------- ------------------------------------- ------------------------------------------------------ --------------------------------------------------------------- ----------------------------------------------------------------------
  Modifiers Encoded within 22q11.2del                                                                                                                                                                                                                                                                                              

  Coding                                           *DiGeorge Syndrome Critical Region 8* (*DGCR8*)   Between LCRA-B                                                   *Dgcr8*                               Global mRNAs                                           Ubiquitous                                                      miRNA biogenesis\
                                                                                                                                                                                                                                                                                                                                   Alzheimer\'s disease\
                                                                                                                                                                                                                                                                                                                                   Schizophrenia

  MiRNAs (7)                                       miR-185                                           Between LCRA-B                                                   miR-185                               *Btk, SERCA2, Camk4, NFAT3c, Mzb1*                     Thymus, brain,\                                                 T and B cell signaling, cardiomyocyte hypertrophy, calcium responses
                                                                                                                                                                                                                                                                   heart, T and B cells                                            

  miR-4761[^a^](#fnT2_1){ref-type="table-fn"}      Between LCRA-B                                    none                                                             --                                    brain                                                  Predicted: Dopamine metabolism and neurotransmitter clearance   

  miR-3618                                         Between LCRA-B\                                   none                                                             --                                    Ubiquitous                                             Predicted: RNA capping\                                         
                                                   5\' UTR of *DGCR8*                                                                                                                                                                                              Gene expression                                                 

  miR-1306                                         Between LCRA-B\                                   miR-1306                                                         *FBLX5, TGF-beta receptor II*         Ubiquitous                                             Predicted: mRNA capping and gene expression                     
                                                   Exon 1 of *DGCR8*                                                                                                                                                                                                                                                               

  miR-6816[^a^](#fnT2_1){ref-type="table-fn"}      Between LCRA-B                                    none                                                             --                                    Not determined                                         unknown                                                         

  miR-1286                                         Within LCRB                                       Only in primates[^e^](#fnT2_5){ref-type="table-fn"}              --                                    Cerebellum                                             unknown                                                         

  miR-649                                          Within LCRD                                       miR-649                                                          *MALT1* (NF-kB pathway)               Oral mucosa,\                                          HSV infection susceptibility                                    
                                                                                                                                                                                                            muscle                                                                                                                 

  RNA transcript affected                          Location on 22q11.2                               Highest RPKM (tissue sites)[^d^](#fnT2_4){ref-type="table-fn"}   Dominant Sites of Tissue Expression   Function                                                                                                               

  LncRNAs (12)                                     DGCR5                                             Within LCRA                                                      40 (cerebellum, cortex)               Brain, pancreas, pituitary                             Targets miR-1180, miR-23b                                       

  DGCR9                                            Within LCRA-B                                     25 (cerebellum)                                                  Brain, pituitary                      Cell proliferation and glucose uptake                                                                                  

  DGCR11                                           Within LCRA-B                                     1 (Skin)                                                         Brain, skin, blood                    Within DGCR2                                                                                                           

  AC004471.10                                      Between LCRA-B                                    4 (testes)                                                       Brain, muscle, skin, testes           Protein homolog TSSK2                                                                                                  

  LINC01311                                        Between LCRA-B                                    2.4 (brain, testes)                                              Ubiquitous                            To be determined                                                                                                       

  AC000067.2                                       Between LCRA-B                                    0.1 (brain)                                                      Arteries, brain                       To be determined                                                                                                       

  LINC00895                                        Between LCRA-B                                    Not reported                                                     Ubiquitous                            To be determined                                                                                                       

  LINC00896                                        Between LCRA-B                                    3.3 (thyroid, pituitary)                                         Pituitary, thyroid                    Regulated by miR-139                                                                                                   

  XXbac-B444P24.14\                                Within LCRB                                       0.8 (pituitary, thyroid)                                         Ubiquitous                            To be determined                                                                                                       
  (ENSG00000273139)                                                                                                                                                                                                                                                                                                                

  XXbac-B33L19.4\                                  Within LCRB                                       1 (testes)                                                       Testes                                To be determined                                                                                                       
  (ENSG00000235578)                                                                                                                                                                                                                                                                                                                

  XXbac-B135H6.18\                                 Between LCRC-D                                    3 (pituitary)                                                    Brain, muscle, pituitary              To be determined                                                                                                       
  (ENSG00000272829)                                                                                                                                                                                                                                                                                                                

  KB1592A4.15\                                     Within LCRD                                       40 (testes)                                                      Testes                                To be determined                                                                                                       
  (ENSG00000197210.7)                                                                                                                                                                                                                                                                                                              

  SnoRNAs (2)                                      SNORA15                                           Between LCRA-B                                                   0.2                                   Nucleolus                                              Nucleolar RNA guide for modifying uridine                       

  SNORA77                                          Between LCRA-B                                    5 (brain) 7 (testes)                                             Nucleolus                             Guide for modifying uridine on 18S rRNA                                                                                

  Modifiers Encoded outside the 22q11.2del locus                                                                                                                                                                                                                                                                                   

  Type of RNA                                      RNA transcript affected                           Location                                                         Murine Homologs                       Confirmed targets                                      Tissue expression                                               Pathways affected[^b^](#fnT2_2){ref-type="table-fn"}

  MiRNAs                                           miR-96a                                           chr7:129774692-129774769                                         miR-96a                               *TBX1, FOXO1, FOXO3a, RECK, EphrinA5 and SAMD9*        Sensory organs, inner ear, eye, nose                            Cilia and hearing

                                                   miR-451a                                          chr17:28861369-28861400                                          miR-451a                              *TBX1, Mif, c-myc, AKT1, SPARC*                        ubiquitous                                                      Wound healing and cellular differentiation
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Read count extremely low in miRbase data set with confirmed biological functions lacking.

Confirmed targets primarily based on luciferase reporter assays.

information from published reports, miRNA prediction programs, and Ingenuity Pathway analyses.

Obtained from uscs genome browser.

MiR-1286 only present in humans, orangutans, gorillas, and chimpanzees.

###### 

Genetic and epigenetic modifiers of 22q11.2 deletion syndrome with disease connections.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Gene name                              Chromosome Location[^a^](#fnT3_1){ref-type="table-fn"}   Function                                                        Human syndromes                                                                                   Mechanism
  -------------------------------------- -------------------------------------------------------- --------------------------------------------------------------- ------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------
  Genes on chromosome 22q11.2                                                                                                                                                                                                                                       

  *TBX1*                                 22q11.2                                                  T-box transcription factor regulates expression of 2000 genes   22q11.2del                                                                                        Interacts with histone3 methyltransferases, BAF60a, and SMAD1

  *DGCR8*                                22q11.2                                                  MicroRNA binding protein                                        22q11.2del                                                                                        Epigenetically regulates gene expression through miRNAs

  *DGCR6*                                22q11.2                                                  Regulates neural crest migration                                CHD^b^ (with PRODH deletion)                                                                      Negatively regulates *TBX1* expression

  Morphogens                                                                                                                                                                                                                                                        

  Retinoic acid                          --                                                       Morphogen involved in embryonic patterning                      22q11.2del-like                                                                                   Complexes retinoic acid receptor to regulate gene expression

  Gestational\                           --                                                       Teratogen during pregnancy                                      22q11.2del-like                                                                                   Affects multiple developmental processes in the embryo, with the pharyngeal apparatus particularly sensitive
  Diabetes                                                                                                                                                                                                                                                          

  Genes at other chromosomal locations                                                                                                                                                                                                                              

  *KMT2*                                 7q36.1                                                   Histone methyltransferase                                       Kleefstra syndrome 2\                                                                             Interacts with TBX1 and mono-methylates lysine 27 on histone 3
                                                                                                                                                                  (neurodevelopmental disorder)                                                                     

  *BAF60a (SMARCD1)*                     12q13.2                                                  Component of the SWI-SNF chromatin remodeling complex           --                                                                                                Component of a chromosome remodeling complex that interacts with TBX1

  *MOZ*                                  8p11.21                                                  Histone acetyl transferase                                      CHD[^b^](#fnT3_2){ref-type="table-fn"}, intellectual disability, and dysmorphic facial features   positively regulated by RA and, in turn affects TBX1 expression

  *SMAD1*                                4q31.21                                                  Signaling protein downstream of Bmp4                                                                                                                              Interacts with TBX1, which antagonizes its association with SMAD4

  *JMJD1C*                               10q21.3                                                  Histone demethylase                                             Rett syndrome and intellectual\                                                                   Demethylates lysine residues on histones
                                                                                                                                                                  disability                                                                                        

  *MINA*                                 3q11.2                                                   Lysine-Specific Demethylase and Histidyl-Hydroxylase            Preeclampsia                                                                                      Demethylates lysine residues on histones

  *KDM7A*                                7q34                                                     Lysine demethylase                                              --                                                                                                Demethylates lysine residues on histones

  *RREB1*                                6p24.3                                                   Zn finger transcription factor                                  --                                                                                                Regulates RAS-responsive elements

  *SEC24C*                               10q22.2                                                  Coat Protein II complex                                         --                                                                                                Involved in protein export from ER to Golgi

  *GLUT3*                                12p13.31                                                 Glucose transporter                                             \-                                                                                                High affinity interaction with glucose to translocate across the membrane

  *KANSL1*                               17q21.31                                                 Histone modification                                            Koolen-De Vries syndrome                                                                          Nuclear protein forming part of a complex that has histone acetyltransferase activity

  *PAX1*                                 20p11.22                                                 Transcription factor                                            Octofaciocervical syndrome                                                                        Regulates embryonic tissue patterning

  *VEGF*                                 6p21.1                                                   Vascular endothelial growth factor                              Tetralogy of Fallot                                                                               Vascular endothelial growth factor supports cell growth

  *FGF8*                                 10q24.32                                                 Fibroblast growth factor                                        Hypogonadotropic hypogonadism 6                                                                   Fibroblast growth factor supports cell growth

  *PDGFRα*                               4q12                                                     Platelet derived growth factor receptor                         --                                                                                                Regulates neural crest cell development

  *SHH*                                  7q36.3                                                   Sonic hedgehog protein                                          Holoprosencephaly 3, Microphthalmia with coloboma 5                                               Regulates Tbx1 expression and vertebrate organogenesis
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Human chromosomal location.

Congenital heart disease.

The Genetic and Epigenetic Regulation Coupled to *TBX1* Functions {#s2}
=================================================================

The congenital malformations associated with 22q11.2del are often linked to the haploinsufficiency of *TBX1* ([@B82]; [@B58]; [@B83]; [@B100]; [@B168]; [@B42]). *TBX1* is expressed at specific regions in the pharyngeal apparatus and in the cardiac progenitors of the second heart field, regulating the expression of nearly 2000 genes ([@B158]; [@B22]; [@B42]). Many excellent reviews detailing the transcriptional role of *TBX1* in the patterning of the pharyngeal arches and pouches have been published ([@B161]; [@B167]; [@B9]; [@B43]; [@B94]; [@B96]; [@B4]; [@B145]). While one might expect that a simple haploinsufficiency of *TBX1* should consistently lead to similar congenital malformations, this is certainly not what happens. It is becoming apparent that genetic and epigenetic changes, both within and outside chromosome 22q11.2, can dramatically sway the clinical phenotypes of 22q11.2del ([@B82]; [@B58]; [@B83]; [@B100]; [@B168]; [@B42]).

To understand how such genetic and epigenetic factors impact *TBX1* and how this may affect the clinical phenotypes requires some knowledge of how TBX1 functions. Recent evidence indicates that *TBX1* interacts with members of the Histone-lysine N-methyltransferase (KMT2)-family ([@B42]). The KMT2 enzymes activate transcription by mono-methylating lysine residues on Histone 3 (H3K4) on chromatin ([**Figure 2**](#f2){ref-type="fig"}) ([@B42]). The TBX1-KMT2 complex regulates the low-level expression of thousands of genes by marking chromatin. In addition, TBX1 interacts with the SWI-SNF-like BAF complex to support chromatin remodeling ([**Figure 2**](#f2){ref-type="fig"}) ([@B22]). These two types of interactions would suggest that small fluctuations in the levels of TBX1 could modulate the expression of thousands of transcripts, with those impacted likely stochastic from cell to cell. Thus, variations in TBX1 levels could underlie the severity of the malformations in the pharyngeal region. What patient to patient differences exist that could affect *TBX1* expression? One is with *DiGeorge Critical Region 6 (DGCR6*), a gene also encoded on the frequently deleted segment of chromosome 22q11.2. DGCR6 down-regulates *TBX1*, impacting neural crest migration within the pharyngeal region ([**Figure 2**](#f2){ref-type="fig"}, [**Table 3**](#T3){ref-type="table"}) ([@B48]; [@B21]). As neural crest cells establish the vasculature of the pharyngeal arch arteries along with the capsule of the thymus, changes in their location would affect the morphogenesis of this region. While the transcript levels of *DGCR6* as well as its homolog, *DGCR6L* should be reduced 50% due to their respective haploinsufficiency in 22q11.2del patients, their levels are extremely variable in 22q11.2del patients ([@B21]). Some individuals actually have much higher levels of DGCR6 compared to normal controls ([@B21]). Such dramatic expression variations in *DGCR6* and *DGCR6L* are epigenetically determined as there is no evidence of maternal or paternal imprinting ([@B21]). Noteworthy, either deletions or duplications of *DGCR6*, in combination with an adjacent gene, *PRODH*, are linked to CHD ([@B45]). These findings suggest that fluctuations in DGCR6 will affect *TBX1* levels, and as a consequence, patterning of the pharyngeal region. While most TBX1 is localized in the nucleus, some is present in the cytosol where a portion is complexed with SMAD1 ([@B41]). This interaction limits the levels of a SMAD1-SMAD4 complex, preventing effective Bone Morphogenic Protein 4 (BMP4) signaling ([**Figure 2**](#f2){ref-type="fig"}) ([@B41]). As Bmp4 has a critical role in the septation of the outflow tracts and remodeling of the arch arteries, disruption of its signaling by modulating TBX1 levels is certain to impact these processes ([@B86]). Bmp4 also regulates early thymus and parathyroid morphogenesis ([@B46]). TBX1 interacts with several additional proteins, albeit the role of these complexes are less well-defined ([@B4]). In summary, alterations in the levels and/or subcellular distribution of TBX1 will certainly impact the severity of the congenital problems.

![Molecular pathways intersecting with *TBX1* with the potential to modulate the clinical severity and penetrance of 22q11.2del. The expression of *TBX1*, a key gene coupled to the patterning of the pharyngeal apparatus, is positively regulated by members of the Fox-family of transcription factors and MOZ. Negative regulators of TBX1 include the defined teratogens, retinoic acid (RA), gestational diabetes, and miR-96 and miR-451a, the latter two miRNAs that target the 3\' untranslated region of TBX1, resulting in its degradation. While most TBX1 resides in the nucleus, wherein it can regulate gene expression, a fraction of TBX1 is localized in the cytosol, where it negatively impacts bone morphogenic protein signaling *via* a complex with SMAD4.](fgene-10-01365-g002){#f2}

The consequence of varying *TBX1* levels in relation to the severity of the congenital malformations in humans is further supported by comparisons with the diverse 22q11.2del mouse models. Multiple mouse lines were originally created with deletions of varying length on chromosome 16 (orthologous to human chromosome 22q11.2) to identify causal genes in the disorder ([**Figure 1**](#f1){ref-type="fig"}) ([@B59]; [@B65]; [@B82]; [@B116]; [@B58]; [@B83]; [@B100]). Comparing the phenotypes in several such mouse lines confirms that changes in *Tbx1* levels affects the extent and severity of the CHD, thymic hypoplasia, and hypoparathyroidism ([@B65]; [@B82]; [@B116]; [@B58]; [@B81]; [@B83]; [@B100]; [@B147]). Yet, relative to humans, mice actually have a lower penetrance of several of the congenital defects in the setting of either the 22q11.2del or just a *Tbx1* haploinsufficiency, most evident with the number of embryos exhibiting a hypoplasia of the thymus. This corresponds to the levels of *TBX1,* since reducing *Tbx1* to 35% normal in the embryos results in a highly penetrant thymic hypoplasia ([@B168]). Are there strategies to circumvent the reduced levels of *TBX1*? Yes, as treating pregnant mice with a histone demethylase inhibitor (tranylcypromine) can increase the methylation levels of H3K4 and partially rescue the cardiovascular anomalies in the *Tbx*1-mutant embryos ([@B42]).

There are several additional regulators of *TBX1* expression that likely have a bearing on 22q11.2del. One is retinoic acid (RA), a metabolite of vitamin A that functions as a natural morphogen involved in the patterning of the 3^rd^, 4^th^, and 6^th^ pharyngeal arch arteries and 3^rd^ PP ([**Figure 2**](#f2){ref-type="fig"}) ([@B110]; [@B153]; [@B24]; [@B155]). Vitamin A deficiency during pregnancy remains a public health issue in developing countries due to its impact on the developing fetus, particularly eye development ([@B10]). High levels of RA can act as a teratogen that causes overlapping 22q11.2del-like phenotypes. This was discovered after pregnant mothers were prescribed RA (tretinoin, isotretinoin) as a clinical treatment for acne, with their infants born with 22q11.2-like congenital malformations ([@B69]; [@B72]; [@B85]; [@B90]; [@B102]; [@B127]; [@B18]). Mechanistically, RA suppresses *TBX1* expression ([@B123]; [@B125]; [@B137]). This was confirmed by using mice created with a haploinsufficiency of *retinaldehyde dehydrogenase 2* (*Rald2*), an enzyme required for RA synthesis. *Rald2^+/-^* embryos produce less RA, increasing the levels of *Tbx1*. In the setting of a *Tbx1* haploinsufficiency, the severity of the heart defects was reduced in the Rald2^+/-^ background ([@B125]). RA also acts to epigenetically alter chromatin accessibility by positively regulating the expression of *Monocytic Leukemia Zinc Finger* (*MOZ/Myst3/Kat6a*), a histone acetyltransferase. MOZ, in turn, positively regulates TBX1 levels, with *Moz*-knock-out mice and those with loss-of-function mutations having less *Tbx1*, along with *Tbx2*, *Tbx5*, and *Tbx9* ([@B123]; [@B57]; [@B155]). In humans, heterozygous MOZ mutations lead to a syndromic disorder comprising CHD, intellectual disability, and dysmorphic facial features ([@B150]). In summary, too much RA leads to similar clinical phenotypes as 22q11.2del, likely through its ability to reduce the expression of various TBX-family members including *TBX1* ([@B83]; [@B100]; [@B40]; [@B104]; [@B173]; [@B168]).

Gestational diabetes is a distinct teratogen affecting pregnancy, with newborns having congenital features overlapping with 22q11.2del ([@B69]; [@B102]; [@B127]; [@B34]). In fact, about 18% of infants with a thymic aplasia who did not have deletions on chromosome 22q11.2 and required a thymic tissue transplant were born to mothers with a clinical history of gestational diabetes ([@B90]). Experimental induction of diabetes in pregnant mice and rats similarly results in a thymic hypoplasia along with intrauterine growth impairment ([@B113]). So how might elevated blood sugar levels lead to 22q11.2del-like presentations? While this is not yet known, there are some emerging clues. Pregestational diabetes reduces the expression of a regulator of RA, *Cytochrome P450 family 26 subfamily A member 1* (*Cyp26a1*), in the caudal region (tailbud) of developing embryos ([@B77]). Cyp26a1 catabolizes RA in various tissues to control the levels of this product, and consequently morphogenesis. One speculation is that elevations in blood sugar levels during gestation may increase the levels of RA in the pharyngeal region, thereby diminishing *TBX1* levels. It is also known that gestational diabetes affects histone modifications and DNA methylation patterns in fetal cord blood, implying an epigenetic effect that may contribute to the 22q11.del phenotypes ([@B52]). These emerging findings suggest that better control of gestational diabetes may aid in diminishing the severity of certain congenital malformations, particularly for embryos who have 22q11.2del.

DiGeorge Syndrome Critical Region 8 and microRNA Contributions to 22q11.2del {#s3}
============================================================================

*DiGeorge Syndrome Critical Region 8 (DGCR8)* is another key gene whose haploinsufficiency in 22q11.2del patients can influence the severity of their clinical problems. It is a nuclear miRNA binding protein required for the biogenesis of microRNAs (miRNAs) ([@B73]; [@B166]; [@B131]). MiRNAs are a family of \~2000 small noncoding RNAs (18-22 nucleotides) that bind to diverse mRNA transcripts, targeting the latter for degradation ([@B79]; [@B49]; [@B88]; [@B6]; [@B157]; [@B67]; [@B129]; [@B2]). DGCR8 binds to primary miRNA (pri-miRNA) transcripts in the nucleus in conjunction with DROSHA, an endoribonuclease (Ribonuclease III) that cleaves pri-miRNAs into precursor miRNAs (pre-miRNAs) ([@B75]; [@B73]). These pre-miRNAs are subsequently exported from the nucleus for further processing into miRNAs. Importantly, such miRNAs regulate cellular homeostasis in almost all tissues, are very stress responsive, and facilitate tissue repair and regeneration ([@B6]; [@B78]; [@B98]). Thus, a 50% reduction in *DGCR8* expression due to 22q11.2del would be predicted to modulate the expression of hundreds of miRNAs. Consistent with this, 22q11.2del patients have a miRNA dysregulation in the peripheral blood, with many miRNAs reduced in expression relative to normal controls ([**Table 2**](#T2){ref-type="table"}) ([@B31]). This dysregulation includes a hypervariable miRNA expression pattern that differs from patient to patient, and interestingly, a coordinated expression of multiple distinct clusters of miRNAs among most 22q11.2del individuals ([@B31]; [@B132]). The distinct miRNA clustering may emanate from physiological responses to the clinical problems.

In mouse models, the haploinsufficiency of *Dgcr8* causes a 30-50% reduction in the overall expression of miRNAs screened in neurons ([@B140]). These miRNA losses worsen as the mice age. One consequence so far described is an abnormal calcium response in the hippocampal pyramidal neurons (CA3-CA1) that leads to premature synaptic neurotransmitter release ([@B38]; [@B39]). Such synaptic disruptions are characteristic of schizophrenia, a frequent presentation in the 22q11.2del patients ([@B60]; [@B61]; [@B159]). The neurological miRNA deficiencies in the *Dgcr8* ^+/-^ mice are similar in the mouse models of 22q11.2del, establishing that a 50% reduction in *Dgcr8* is key to the miRNA losses ([@B39]). Interestingly, DGCR8 has functions unrelated to miRNA processing, instead regulating splicing processes in embryonic stem cells, a finding that may reveal more complexities concerning 22q11.2del ([@B25]).

In addition to *DGCR8*, the frequently deleted segment of chromosome 22q11.2 leads to a haploinsufficiency of 7 miRNAs ([**Figure 1**](#f1){ref-type="fig"}, [**Table 2**](#T2){ref-type="table"}). Six are clustered near *DGCR8*. MiR-185 has the strongest connection to the clinical phenotypes of 22q11.2del, detected at 0.4 X normal levels in peripheral blood samples ([@B31]). It is expressed in cardiac tissue, immune cells, and in the brain, targeting *Marginal Zone B1 Protein* (*Mzb1*), *Bruton's Tyrosine Kinase* (*Btk*), *Calmodulin Kinase 4* (*Camk4*), *Sarco/endoplasmic Reticulum Ca^2+-^ATPase* (*Serca2*), and *Nuclear Factor of Activated T cells 3c* (*Nfat3c*) ([@B39]; [@B12]; [@B64]). A common theme regarding these miR-185 targets is calcium signaling, central to many cellular processes ([**Table 2**](#T2){ref-type="table"}). The haploinsufficiency of miR-185 in hippocampal neurons results in premature synaptic transmissions, partly through changes in *Serca2* and *Nfatc* levels, with these genes controlling or being regulated by intracellular calcium changes, respectively ([@B39]). Moreover, enforced expression of miR-185 in thymocytes attenuates T cell development by a disruption of the T cell receptor controlled calcium response ([@B12]). MiR-185 also controls cardiac hypertrophy by targeting *Nfatc* in myocardial cells ([@B64]). In B cells, the haploinsufficiency of miR-185 is linked to increased autoantibody production, and this may involve increases in the levels of *Bruton's tyrosine kinase* (Btk), a target of miR-185 ([@B13]). Notably, 22q11.2del patients can have clinical phenotypes related to the disruption of all of these pathways; abnormal neurotransmitter release, low T cell output, cardiac hypertrophy, and autoimmunity. Two additional miRNAs, miR-3618 and miR-1306, are located at the 5' untranslated region and within exon 1 of *DGCR8*, respectively ([**Table 2**](#T2){ref-type="table"}). While miR-1306 is encoded in most eukaryotic species, miR-3618 is restricted to primates ([@B99]). MiR-1306 targets *F-box/Leucine rich repeat 5* (*FBLX5*), affecting epithelial to mesenchymal transitions and *TGF beta-receptor 2*, which is involved in the TGF-beta-SMAD4 signaling process ([**Figure 2**](#f2){ref-type="fig"}) ([@B53]; [@B164]). Other haploinsufficient miRNAs include miR-1286, selectively encoded in advanced primates, with *in situ* hybridization revealing its expression in the occipital cortex ([@B111]). MiR-649, located within the LCRD segment of 22q11.2, targets *MALT1*, a component of a complex of proteins that activate NF-κB in lymphocytes. MiR-649 enhances Herpes Simplex Virus susceptibility, likely through effects on the NF-κB pathway ([@B170]). Several miRNA target prediction programs have been applied to the 7 miRNAs encoded on chromosome 22q11.1 to identify linked pathways that relate to clinical phenotypes. An overlapping set of these miRNAs can target *TBX1*, *KAT8 regulatory NSL complex subunit 1* (*KANSL1*), *Glucose Transporter 3* (*GLUT3*, SLC2A3), and *Ras Responsive Element Binding protein 1* (*RREB1*) ([@B14]; [@B74]). Several of these targets are discussed in a subsequent section in relation to their roles in 22q11.2del. Four of the miRNAs regulate transcripts linked to schizophrenia ([@B99]).

Interestingly, there are 2 miRNAs encoded on other chromosomes that target *TBX1*. One is miR-96, mutations in which cause a non-syndromic hearing loss in humans ([**Figure 2**](#f2){ref-type="fig"}) ([@B97]; [@B44]). In a feed-back loop, TBX1 represses miR-96, suggesting that alterations in the levels of *TBX1* may impact hearing loss, consistent with the auditory problems reported for some but not all 22q11.2del patients ([@B44]). A second is miR-451, which is involved in wound healing and has been shown to target *TBX1* transcripts ([@B146]; [@B108]). Ongoing research efforts to identify the different miRNA targets are uncovering multiple intersecting pathways connected with the developmental and neurological manifestation of 22q11.2del ([**Table 2**](#T2){ref-type="table"}). The fact that the expression of many distinct miRNAs fluctuate over time and are variable from patient to patient likely explains some of the post-natal complications that differ among 22q11.2del patients ([@B31]). Future directions for such patients may be clinical interventions to improve DGCR8 functions, with recent experiments reporting that protoporphyrins can enhance miRNA biogenesis in DGCR8-haploinsufficient cells ([@B5]; [@B126]).

Emerging Noncoding RNAs and Their Potential Roles in 22q11.2del {#s4}
===============================================================

Adding further complexity to 22q11.del are the 12 long noncoding RNAs (lncRNAs) embedded in the frequently deleted segment of chromosome 22q11.2 ([**Table 2**](#T2){ref-type="table"}). LncRNAs can act as scaffold RNAs, transcriptional assembly hubs, regulators of chromatin accessibility and genome stability ([@B3]; [@B76]; [@B117]; [@B36]). They exhibit limited evolutionary sequence conservation and are generally expressed at levels much lower than protein coding genes ([@B20]; [@B63]; [@B33]; [@B162]; [@B171]). In spite of the accumulating discoveries detailing the functions of numerous lncRNAs, relatively little is known about the 12 that are frequently deleted on chromosome 22q11.2. As the curation of lncRNAs in the human genome is incomplete, additional lncRNAs are likely to be identified on chromosome 22q11.2, while some of those currently compiled may be invalidated. Four lncRNAs, DGCR5, DGCR9, LINC01311, and LINC00896 have high enough RPKM values (Reads per Kilobase of transcripts per Million mapped reads) to suggest functionality, particularly as each is expressed in the biologically relevant tissue ([**Table 2**](#T2){ref-type="table"}). Findings to date suggest that several of these lncRNAs could affect the clinical presentations of 22q11.2del, but this is only inferred based on what is known about these lncRNAs in non-22q11.2del patients. DGCR5 and Lnc00896 were up-regulated 9- and 5- fold in patients with lung adenocarcinomas, implying a role in cell growth and survival ([@B143]). In a separate study of lung cancer patients, DGCR5 was down-regulated, and its target, miR-1180, was increased in expression ([@B23]). Elevations in miR-1180 reduces apoptosis ([@B149]). DGCR5 also functions as a competing RNA for miR-23b, causes increases in the targets of this miRNA, PTEN and BTG1 ([@B160]). Lnc00896 is regulated by miR-139, although the importance of this remains unknown ([@B143]). DGCR11 is up-regulated 2-fold in hepatocellular cancers, again its role remaining undefined ([@B169]). AC004471.10 has a protein coding analog in both the murine and cow genomes, termed Testes Specific Serine Kinase 2 (TSSK2), and lies downstream of TSSK1A ([@B87]). The significance of this lncRNA-protein coding region homology remains unclear. XXbac-B444P24.14 was identified in a screen for differentially regulated lncRNAs in multiple myeloma ([@B124]). As with many of the annotated lncRNAs currently curated in the human genome, future studies will need to ascertain the functional contributions of those haploinsufficient due to 22q11.2del and assess the consequences of this on the clinical phenotypes.

Along with the miRNAs and lncRNAs encoded on chromosome 22q11.2 are two small nucleolar RNAs (snoRNAs), SNORA15, and SNORA77 ([**Table 2**](#T2){ref-type="table"}). Ranging in size from 60--300 nucleotides, snoRNAs are generated from intronic regions. They assemble with a set of proteins in the nucleolus to facilitate ribosomal RNA processing ([@B95]). Both SNORA15 and SNORA77 regulate the conversion of uridines to pseudouridines to improve the folding and stabilization of rRNAs ([@B37]). The expression of SNORA15 is altered in cancer, but again how the haploinsufficiency of either of the two snoRNAs affects biological functions in the context of 22q11.2del remains an open question ([@B163]).

Taken together, it is clear that the haploinsufficiency of diverse noncoding RNAs and the extensive dysregulation of the miRNAs within this group will impact both developmental processes during embryogenesis and post-natal cardiac, immune, and neurological functions. Identifying the pathways affected by these diverse noncoding RNAs may better guide clinical management of the 22q11.2del patients.

Diverse Genetic Polymorphisms Affecting 22q11.2del Phenotypes {#s5}
=============================================================

Patients with both deletions and duplications of chromosome 22q11.2 and those with loss- or gain- of-function mutations in *TBX1* often have overlapping congenital problems that still vary in severity ([@B40]; [@B161]; [@B158]; [@B141]; [@B173]; [@B22]; [@B120]; [@B4]). Moreover, identical mutations in *TBX1* present among several members of the same family resulted in distinct clinical phenotypes ([@B161]). These findings further support the idea that selected genetic and/or epigenetic changes can impact the severity of the clinical complications for 22q11.2del patients ([@B82]; [@B58]; [@B83]; [@B100]; [@B147]; [@B158]; [@B168]; [@B22]; [@B4]; [@B42]). This is evident with recent studies revealing numerous genetic differences among the 22q11.2del patients that lie outside the affected locus, potentially affecting disease severity and penetrance ([@B51]; [@B103]; [@B29]; [@B74]). Identified by targeted exome, whole genome, and RNA sequencing strategies, SNPs, copy number variants (CNVs), DNA coding sequence differences and noncoding alterations have been discovered. For example, whole exome sequencing of 184 different 22q11.2del patients was used to identify rare deleterious SNPs ([@B51]). This screen uncovered polymorphisms in several genes selectively in those 22q11.2del patients with CHD. Several of the SNPs are in genes that regulate histone demethylation, *Jumonji Domain Containing 1C* (*JMJD1C*), *MYC Induced Nuclear Antigen* (*MINA*), and *Lysine-Specific Demethylase* (*KDM7A*). This once again reveals an epigenetic component to 22q11.2del. SNPs have also been reported in *Ras Responsive Element Binding protein 1* (*RREB1*) and *SEC24 family member C* (*SEC24C*) selectively in the 22q11.2del with CHD.

CNV analyses have revealed a connection between those 22q11.2del patients who have CHD with a duplication of *GLUT3* (also known as *SLC2A3*), located on chromosome 12p13.3 ([@B103]). Its duplication is only pathogenic in conjunction with 22q11.2del (Odds ratio = 5.08) ([@B103]). Of the 5 glucose transporters, GLUT3 has the highest affinity and greatest transport capacity for glucose ([@B136]). An independent screen for CNVs in 253 22q11.2del patients identified a duplication of the first 3 exons of the *KANSL1* (chromosome 17q21.31), contributing to an increased odds ratio for CHD (OR = 2.75) ([@B74]). KANSL1 is part of protein complex that acetylates histones to regulate gene expression ([@B105]). How the duplication of 3 exons of *KANSL1* increases the likelihood of CHD remains uncertain, but a recurring theme of histone modifications in the context of 22q11.2del is evident. *KANSL1* is also linked to gene pathways regulated by miRNAs, discussed in a preceding section. In a separate screen for CNVs in miRNAs, deletions and duplications of 11 distinct miRNAs were uncovered in 22q11.2del patients, with at least 1 miRNA affected per individual ([@B14]).

Mouse Studies Revealing Additional Candidate Genes Influencing 22q11.2del {#s6}
=========================================================================

Complementing the human sequencing are various mouse studies suggesting additional candidate genes could affect the penetrance and/or severity of 22q11.2del. Among these are *Vascular endothelial growth factor* (*Vegf*), *Fibroblast growth factor 8* (*Fgf8*), and *Platelet derived growth factor receptor* (*Pdgfr*) ([**Table 3**](#T3){ref-type="table"}) ([@B154]; [@B139]; [@B155]). In mice, reductions in *Vegf* recapitulate the cardiac defects of 22q11.2del ([@B139]; [@B71]). Mice haploinsufficient in both *Tbx1* and *Fgf8* (*Tbx1* ^+/−^ *Fgf8* ^+/−^) have a higher penetrance of aortic arch artery defects, with Tbx1 regulating *Fgf8* expression ([@B154]). These results led one group of investigators to speculate that *VEGF* and/or *FGF8* expression differences in humans could affect the severity of clinical phenotypes in 22q11.2del ([@B139]; [@B71]). In one case study, a family with low levels of *VEGF* had several members diagnosed with Tetralogy of Fallot, which occurs in patients with 22q11.2del ([@B71]). Another possible epigenetic regulator is *Pdgfrα*, which is expressed in neural crest cells throughout the pharyngeal region ([@B148]; [@B137]). Its targeted elimination in mice causes very similar cardiac anomalies as reported for 22q11.2del ([@B148]). Interestingly, *Pdgfrβ* appears to provide some functional redundancy in the absence of *Pdgfrα*, as the elimination of both receptors in neural crest cells results in a near complete penetrance of the cardiac anomalies along with a thymic aplasia ([@B148]; [@B122]; [@B137]). Other candidate genes identified in mouse models include *Pax1*, *Pax3*, *Rarb*, *Cyp26b1*, *Hoxa3*, *Hoxb1*, *Hoxb3*, *Hoxb4*, and *Hoxd4*, each of which is expressed either throughout the entire pharyngeal apparatus or at selected regions. Loss-of-function mutations in human *PAX1* cause otofaciocervical syndrome coupled with immunodeficiency, the latter due to the resulting thymic aplasia ([@B115]; [@B114]). In summary, it is likely that polymorphisms and/or mutations that impact the expression/function of many of the genes coupled to the patterning of the pharyngeal apparatus as well as neurological processes will be identified based on their capacity to modulate the clinical manifestations of 22q11.2del.

A further observation from the different mouse models is the strain dependent severity of the CHD and thymic anomalies, which reveals the effects of genetic differences ([@B147]). Thus, the original 129SvEv background in which most of the 22q11.2del mouse models were generated has the lowest penetrance of the congenital malformations ([@B65]; [@B82]; [@B58]; [@B83]; [@B100]). Backcrossing these mice onto the C57BL/6 background yields a more penetrant phenotype, particularly in regards to the thymic hypoplasia ([@B147]). Of relevance, this strain of mice is more sensitive to stress, as assessed by the higher corticosterone levels in the blood ([@B118]). Children with 22q11.2del have higher levels of cortisol relative to age-matched controls ([@B56]). Elevations in cortisol can reduce T cell output from the thymus ([@B11]). Studies in a zebrafish model suggest elevated cortisol levels during embryogenesis are detrimental to cardiac functions ([@B109]). The connection between stress, tissue repair and regeneration, and miRNAs is well-established, and the dysregulation of miRNAs described above will likely be impacted by the cortisol levels in 22q11.2del patients. Finally, the severity and penetrance of the congenital malformations may be related to epigenetic modifiers that affect tissue repair and regeneration during embryogenesis. Notably, the 4^th^ pharyngeal arch artery is either missing and/or poorly developed in nearly 100% of the murine 22q11.2 del embryos when assessed at embryonic e10.5 (equivalent to human embryonic week 7) ([@B81]; [@B62]). However, this penetrance drops dramatically between e12.5-e18.5, such that only 30% of the 22q11.2del pups have CHD at term ([@B81]). This indicates a regenerative or corrective process in genetically identical embryos, which could be explained by epigenetic modifiers, a possibility that requires further analysis.

Independent Chromosomal Deletions in Relation to 22q11.2del {#s7}
===========================================================

In an analysis of \>1400 22q11.2del patients, 1% were found to have secondary mutations at other loci ([@B101]; [@B93]; [@B68]). These secondary mutations, including some affecting the presumed normal allele of chromosome 22q11.2, are resulting in dual diagnoses ([@B27]). A few of the more prominent diagnoses include CHARGE (Coloboma, heart defects, atresia choanae, growth retardation, genital and ear anomalies) syndrome, cystic fibrosis, G6PD deficiency, 17q12 deletion syndrome, and von Willebrand disease ([@B101]; [@B93]; [@B27]). Whether these secondary mutations at distinct loci influence the expression of genes on chromosome 22q11.2 has not been assessed. There are also reports of patients with 22q11.2del-like phenotypes due to chromosomal deletions at unrelated loci. Among these are microdeletions on 10p13, 4q34, and 3p12.3 ([**Table 1**](#T1){ref-type="table"}). Terminal deletions on the short arm of chromosome 10 cause 10p syndrome. Described in over 46 patients, the phenotypes are split into two: DiGeorge syndrome 2 (DGS2) (OMIM\# 601362) and hypoparathyroidism, sensorineural deafness and renal dysplasia (HDR) (OMIM\# 146255) ([@B152]). DGS2 results from haploinsufficiency of the more proximal region of 10p13-10p14. The resulting cardiac anomalies and thymic hypoplasia are coupled to a haploinsufficiency of *BRUNOL3* (*NAPOR, CUGBP2, ETR3*) ([@B80]). HDR is a separate syndrome involving deletions in the more terminal region of chromosome 10 (10p14-10pter) that result in a hemizygosity of *GATA3* ([@B84]). Chromosomal deletions of the terminal end of 4q34 cause chromosome 4q syndrome, with at least one patient reported with clinical phenotypes of 22q11.2del ([@B30]; [@B142]). A 371-kb interstitial deletion of 3p12.3 was reported for a male child with a clinical presentation of 22q11.2del ([@B26]). Two miRNAs, miR-1243 and miR-4273 along with the *Zinc Finger Protein 717* (*ZNF717)* are affected by this deletion, resulting in DiGeorge-like syndrome and renal insufficiency. Given the clinical overlap among these different microdeletions, it is anticipated that several may affect *TBX1* expression and/or modulate histone modifications among cells differentiating within the pharyngeal region.

Summary {#s8}
=======

Rapid advances in our understanding of the molecular mechanisms underpinning the heterogeneous clinical presentations of 22q11.2del are creating exciting new possibilities for earlier diagnosis and better treatment strategies for affected individuals. The introduction of TREC testing as part of newborn screening throughout the US and in other countries has accelerated the time when infants with 22q11.2del are diagnosed, and this will mean in more rapid and appropriate clinical interventions ([@B35]). Innovations in whole genome sequencing and DNA-based microarrays also make possible an accurate diagnosis of 22q11.2del in the developing fetus using maternal blood sampling ([@B165]; [@B130]). These non-invasive prenatal tests are very sensitive and have low false positive discovery rates ([@B119]). Improvements in sequencing limited amounts of fetal DNA from maternal sampling is moving the field to 1^st^ trimester screening ([@B138]; [@B54]) (ClinicalTrials.gov Identifier: NCT03375359). This is important because the pharyngeal defects arise during this period. Mitigating the damage to the pharyngeal region in *TBX1*-haploinsufficient embryos at this time point will definitely improve clinical outcomes. In the post-natal period, managing physiological stress should improve vulnerabilities due to miRNA dysregulation, arising from the reduced levels of *DGCR8*. The identification of small drugs able to modulate the consequences of the haploinsufficiency of both *TBX1* and *DGCR8* suggest new strategies for reducing the clinical penetrance and severity of 22q11.2del ([@B5]; [@B42]). In summary, DNA and RNA sequencing approaches are unveiling new genetic and epigenetic modifiers among the 22q11.2del cohort that have a significant impact on disease penetrance and severity. Identifying and understanding these genetic and epigenetic regulators in an individualized manner for each 22q11.2del patient will direct future care in order to minimize disease severity.
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